The regulation of apoptosis by activin and transforming growth factor-β in early neoplastic and tumorigenic ovarian surface epithelium

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 5, 2001, Pages 2125-2135

  Choi, Kyung Chul ^a   Kang, Sung Keun ^a   Tai, Chen Jei ^a   Auersperg, Nelly ^a   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; FOLLISTATIN; INHIBIN; PROTEIN BAX; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTIVIN RECEPTORS; ACTIVINS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; FEMALE; HUMANS; INHIBINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, GROWTH FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

FALLOPIA; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0035000225     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.5.2125     Document Type: Article

References (61)

1. Risch HA. 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 90:1774-1786.
2. Auersperg N, Maines-Bandiera SL, Kruk PA. 1995 Human ovarian surface epithelium: growth patterns and differentiation. In: Sharp F, Mason P, Blacket T, Berek J, eds. Ovarian cancer 3. London: Chapman & Hall; 157-169.
3. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC. 1993 Growth regulation and transformation of ovarian epithelium. Cancer. 71:545-551.
4. Nicosia SV, Saunders BO, Acevedo-Duncan ME, Setrakian S, Degregorio R. 1991 Biopathology of Ovarian Mesothelium. In: Farniliari G, Makabe S, Motta PM eds. Ultrastructure of the ovary. New York: Kluwer; 287-310.
5. Fathalla MF. 1971 Incessant ovulation: a factor in ovarian neoplasia? Lancet. 2:163.
6. Godwin AK, Testa JR, Hamilton TC. 1993 The biology of ovarian cancer development. Cancer. 71:530-536.
7. Piver MS, Baker TR, Piedmonte M, Sandecki AM. 1991 Epidemiology and etiology of ovarian cancer. Semin Oncol. 18:177-185.
8. Hamilton TC. 1992 Ovarian cancer. I. Biology. Curr Prob Cancer. 16:1-57.
9. Rao BR, Slotman BJ. 1991 Endocrine factors in common epithelial ovarian cancer. Endocr Rev. 12:14-26.
10. Westerman AM, Beijnen JH, Moolenaar WH, Rodenhuis S. 1997 Growth factors in human ovarian cancer. Cancer Treat Rev. 23:113-131.
11. Shoham Z. 1994 Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril. 62:433-448.
12. Maines-Bandiera S, Kruk PA, Auersperg N. 1992 Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol. 167:729-735.
13. Auersperg N, Pan J, Grove BD, et al. 1999 E-cadherin induces mesenchymalto-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA. 96:6249-6254.
14. Ong A, Maines-Bandiera S, Roskelley CD, Auersperg N. 2000 An ovarian adenocarcinoma line derived from SV40/E-cadherin-transfected normal ovarian surface epithelium. Int J Cancer. 85:430-437.
15. Vale W, Rivier C, Hsueh A, et al. 1988 Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res. 44:1-34.
16. Ling N, Ying SY, Ueno N, et al. 1986 Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature. 321:779-782.
17. Vale W, Rivier J, Vaughan J, et al. 1986 Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature. 321:776-778.
18. Eramaa M, Heikinheimo K, Tuuri T, Hilden K, Ritvos O. 1993 Inhibin/activin subunit mRNA expression in human granulosa-luteal cells. Mol Cell Endocrinol. 92:R15-R20.
19. Tuuri T, Eramaa M, Van Schaik RHN, Ritvos O. 1996 Differential regulation of inhibin/activin α- and βA-subunit and follistatin mRNAs by cyclic AMP and phorbol ester in cultured human granulosa-luteal cells. Mol Cell Endocrinol. 121:1-10.
20. Eramaa M, Hilden K, Tuuri T, Ritvos O. 1995 Regulation of inhibin/activin subunit messenger ribonucleic acids (mRNAs) by activin A and expression of activin receptor mRNAs in cultured human granulosa-luteal cells. Endocrinology. 136:4382-4389.
21. Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL. 1996 Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology. 137:486-494.
22. Fukuda J, Ito I, Tanaka T, Leung PCK. 1998 Cell survival effect of activin against heat shock stress on OVCAR-3. Life Sci. 63:2209-2220.
23. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL. 1997 Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab. 82:3720-3727.
24. Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PCK. Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol Cell Endocrinol. In press.
25. Barrack ER. 1997 TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate. 31:61-70.
26. Hu PP, Datto MB, Wang XF. 1998 Molecular mechanisms of transforming growth factor-β signaling. Endocr Rev. 19:349-363.
27. Berchuck A, Rodriguez G, Olt G, et al. 1992 Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am J Obstet Gynecol. 166:676-684.
28. Havrilesky LJ, Hurteau JA, Whitaker RS, et al. 1995 Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res. 55:944-948.
29. Marth C, Lang T, Koza A, Mayer I, Daxenbichler G. 1990 Transforming growth factor-β and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Lett. 51:221-225.
30. Zhou L, Leung BS. 1992 Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors α and β1. Biochim Biophys Acta. 1180:130-136.
31. Bartlett JM, Rabiasz GJ, Scott WN, Langdon SP, Smyth JF, Miller WR. 1992 Transforming growth factor-β mRNA expression and growth control of human ovarian carcinoma cells. Br J Cancer. 65:655-660.
32. Jakowlew SB, Moody TW, Mariano JM. 1997 Transforming growth factor-β receptors in human cancer cell lines: analysis of transcript, protein and proliferation. Anticancer Res. 17:1849-1860.
33. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY. 1999 Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma. Cancer. 85:658-668.
34. Kruk PA, Maines-Bandiera SL, Auersperg N. 1990 A simplified method to culture human ovarian surface epithelium. Lab Invest. 63:132-136.
35. Li W, Olofsson JI, Jeung EB, Krisinger J, Yuen BH, Leung PCK. 1994 Gonadotropin-releasing hormone and cyclic AMP positively regulate inhibin subunit messenger RNA levels in human placental cells. Life Sci. 55:1717-1724.
36. Peng C, Ohno T, Koh LY, Chen VTS, Leung PCK. 1999 Human ovary and placenta express messenger RNA for multiple activin receptors. Life Sci. 64:983-994.
37. Bargou RC, Daniel PT, Mapara MY, et al. 1995 Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 60:854-859.
38. Tokunaga K, Nakamura Y, Sakata K, et al. 1987 Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 47:5616-5619.
39. Sambrook J, Fritsch EF, Maniatis T. 1989 Molecular cloning; a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory: 18.47-18.66.
40. Wang QF, Tilly KI, Tilly JL, et al. 1996 Activin inhibits basal and androgen- stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology. 137:5476-5483.
41. Wang TTY, Phang JM. 1995 Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55:2487-2489.
42. Zheng W, Luo MP, Welt C, et al. 1998 Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 69:23-31.
43. Mathews LS. 1994 Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev. 15:310-325.
44. Woodruff TK. 1998 Regulation of cellular and system function by activin. Biochem Pharmacol. 55:953-963.
45. Mather JP, Moore A, Li RH. 1997 Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc Soc Exp Biol Med. 215:209-222.
46. Schneyer AL, Rzucidlo DA, Sluss PM, Crowley Jr WF. 1994 Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology. 135:667-674.
47. Wang QF, Khoury RH, Smith PC, et al. 1996 A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab. 81:1434-1441.
48. Delbaere A, Sidis Y, Schneyer AL. 1999 Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin. Endocrinology. 140:2463-2470.
49. McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, Risbridger GP. 1997 Growth inhibitory response to activin A and B by human prostate tumor cell lines, LNCaP and DU145. J Endocrinol. 154:535-545.
50. Ho I, Minegishi T, Fukuda J, Shinozaki H, Auersperg N, Leung PCK. 2000 Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma. Br J Cancer. 82:1415-1420.
51. Bartlett JM, Landon SP, Scott WN, et al. 1997 Transforming growth factor-β isoform expression in human ovarian tumors. Eur J Cancer 33:2397-2403.
52. Hurteau J, Rodriguez GC, Whitaker RS, et al. 1994 Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 74:93-99.
53. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast Jr RC, Boyer CM. 1990 The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol. 75:255-262.
54. Koseki T, Yamato K, Krajewski S, Reed JC, Tsujimoto Y, Nishihara T. 1995 Activin A-induced apoptosis is suppressed by BCL-2. FEBS Lett. 376:247-250.
55. Koseki T, Yamato K, Ishisaki A, Hashimoto O, Sugino H, Nishihara T. 1998 Correlation between Bcl-X expression and B-cell hybridoma apoptosis induced by activin A. Cell Signal. 10:517-521.
56. Chen W, Woodruff TK, Mayo KE. 2000 Activin A-induced HepG2 liver cell apoptosis: Involvement of activin receptors and Smad proteins. Endocrinology. 141:1263-1272.
57. Massague J. 1992 Receptors for the TGF-β family. Cell. 69:1067-1070.
58. Lafon C, Mathieu C, Guerrin M, Pierre O, Vidal S, Valette A. 1996 Transforming growth factor β1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ. 7:1095-1104.
59. Chao DT, Korsmeyer S. 1998 Bcl-2 family regulators of cell death. Annu Rev Immunol. 16:395-419.
60. Minn AJ, Swain RE, Ma A, Thompson CB. 1998 Recent progress on the regulation of apoptosis by bcl-2 family members. Adv Immunol. 70:245-279.
61. Lapointe J, Fournier A, Richard V, Labrie C. 1999 Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology. 140:416-421.